Feasibility Study for Repurposing RET Inhibitors
ConditionCachexia-Anorexia Syndrome
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Oklahoma
About this trial
The purpose of this study is to assess the effects of selpercatinib on cachexia and anorexia in patients diagnosed with NSCLC, colorectal cancer, or pancreatic cancer.
Eligibility criteria
Qualifiers
Histologically confirmed and documented locally advanced or metastatic NSCLC, pancreatic ductal adenocarcinoma, or colorectal cancer
Patient is currently receiving platinum-based therapy for cancer treatment
Patients on stable EPI
Written informed consent signed and dated by the patient prior to the performance of any study-specific procedures, sampling, or analyses
Disqualifiers
ECOG Performance Score of 3 or 4
Is pregnant or plans to become pregnant during study duration (if patient is of childbearing potential) or plans to make someone pregnant during study duration.
Patient has not experienced significant weight loss (defined as loss of >5% body weight in the past 6 months, OR loss of >2% body weight in the past 6 months with BMI < 20)†
Absolute neutrophil count (ANC) <1.5 x 109/L
Trial design
Treatments tested in this trial
- Selpercatinib
- Strength Assessment
Treatment groups
7 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Oklahoma
Lead sponsor
Presbyterian Health Foundation
Collaborator
Source ClinicalTrials.gov